{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:45:23Z","timestamp":1773135923020,"version":"3.50.1"},"reference-count":40,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,6]]},"abstract":"<jats:p><jats:italic>CYP2A6<\/jats:italic>, <jats:italic>CYP2B6<\/jats:italic>, and <jats:italic>UGT1A9<\/jats:italic> genetic polymorphisms and treatment response after a three-day course of artesunate-mefloquine was investigated in 71 Burmese patients with uncomplicated <jats:italic>Plasmodium falciparum<\/jats:italic> malaria. Results provide evidence for the possible link between <jats:italic>CYP2A6<\/jats:italic> and <jats:italic>CYP2B6<\/jats:italic> polymorphisms and plasma concentrations of artesunate\/dihydroartemisinin and treatment response. In one patient who had the <jats:italic>CYP2A6*1A\/*4C<\/jats:italic> genotype (decreased enzyme activity), plasma concentration of artesunate at one hour appeared to be higher, and the concentration of dihydroartemisinin was lower than for those carrying other genotypes (415 versus 320 ng\/mL). The proportion of patients with adequate clinical and parasitologic response who had the <jats:italic>CYP2B6*9\/*9<\/jats:italic> genotype (mutant genotype) was significantly lower compared with those with late parasitologic failure (14.0% versus 19.0%). Confirmation through a larger study in various malaria-endemic areas is required before a definite conclusion on the role of genetic polymorphisms of these drug-metabolizing enzymes on treatment response after artesunate-based combination therapy can be made.<\/jats:p>","DOI":"10.4269\/ajtmh.13-0531","type":"journal-article","created":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T07:04:23Z","timestamp":1401779063000},"page":"361-366","source":"Crossref","is-referenced-by-count":10,"title":["Preliminary Investigation of the Contribution of CYP2A6, CYP2B6, and UGT1A9 Polymorphisms on Artesunate-Mefloquine Treatment Response in Burmese Patients with Plasmodium falciparum Malaria"],"prefix":"10.4269","volume":"91","author":[{"given":"Papichaya","family":"Phompradit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonuch","family":"Muhamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurak","family":"Cheoymang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesara","family":"Na-Bangchang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Expert Rev Clin Pharmacol","first-page":"307","article-title":"Emerging artemisinin resistance in the border areas of Thailand","volume":"6","author":"Na-Bangchang","year":"2013"},{"key":"R2","series-title":"Eur J Clin Pharmacol","first-page":"687","article-title":"Distribution of mefloquine in the blood of Thai patients with acute uncomplicated falciparum malaria following administration of therapeutic doses of artesunate","volume":"67","author":"Na-Bangchang","year":"2011"},{"key":"R3","series-title":"N Engl J Med","first-page":"2619","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008"},{"key":"R4","series-title":"N Engl J Med","first-page":"540","article-title":"Artemisinin-resistant malaria in Asia","volume":"361","author":"Noedl","year":"2009"},{"key":"R5","series-title":"Trop Med Int Health","first-page":"211","article-title":"In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003","volume":"11","author":"Vijaykadga","year":"2006"},{"key":"R6","series-title":"Malar J","first-page":"263","article-title":"Identification of resistance of Plasmodium falciparum to artesunate-mefloquine combination in an area along the Thai-Myanmar border: integration of clinico-parasitological response, systemic drug exposure, and in vitro parasite sensitivity","volume":"12","author":"Na-Bangchang","year":"2013"},{"key":"R7","series-title":"Southeast Asian J Trop Med Public Health","first-page":"216","article-title":"Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone","volume":"27","author":"Edstein","year":"1996"},{"key":"R8","series-title":"Lancet Infect Dis","first-page":"760","article-title":"Pharmacogenetics of antimalarial drugs: effect on metabolism and transport","volume":"9","author":"Kerb","year":"2009"},{"key":"R9","series-title":"Southeast Asian J Trop Med Public Health","first-page":"575","article-title":"The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers","volume":"35","author":"Na-Bangchang","year":"2004"},{"key":"R10","series-title":"Bull World Health Organ","first-page":"392","article-title":"In vitro sensitivity of Plasmodium falciparum to artesunate in Thailand","volume":"77","author":"Wongsrichanalai","year":"1997"},{"key":"R11","series-title":"Assessment and Monitoring of Antimalarial Drug Efficacy for Treatment of Uncomplicated Falciparum Malaria. (WHO\/HTM\/RBM\/2003.50)","author":"World Health Organization","year":"2003"},{"key":"R12","series-title":"Am J Trop Med Hyg","first-page":"978","article-title":"Plasmodium falciparum parasites in French Guiana: limited genetic diversity and high selfing rate","volume":"61","author":"Ariey","year":"1999"},{"key":"R13","series-title":"Exp Parasitol","first-page":"207","article-title":"Plasmodium falciparum: a simple polymerase chain reaction method for differentiating strains","volume":"75","author":"Wooden","year":"1992"},{"key":"R14","series-title":"Parasitol Today","first-page":"303","article-title":"PCR and strain identification in Plasmodium falciparum","volume":"9","author":"Wooden","year":"1993"},{"key":"R15","series-title":"Southeast Asian J Trop Med Public Health","first-page":"963","article-title":"Development and validation of a liquid chromatography-mass spectrometry method for the simultaneous quantification of artesunate and dihydroartemisinin in human plasma","volume":"39","author":"Thuy","year":"2008"},{"key":"R16","series-title":"Molecular Cloning: A Laboratory Manual","author":"Sambrook","year":"1989"},{"key":"R17","series-title":"Biochem Biophys Res Commun","first-page":"810","article-title":"A novel single nucleotide polymorphism altering stability and activity of CYP2a6","volume":"281","author":"Ariyoshi","year":"2001"},{"key":"R18","series-title":"FABAD J Pharm Sci","first-page":"17","article-title":"Do CYP2A6 and GSTM1 genotypes have any impact on genotoxicity in healthy Turkish smokers","volume":"30","author":"Neslihan","year":"2005"},{"key":"R19","series-title":"Br J Clin Pharmacol","first-page":"511","article-title":"Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism","volume":"54","author":"Yoshida","year":"2002"},{"key":"R20","series-title":"Pharmacogenetics","first-page":"399","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001"},{"key":"R21","series-title":"Drug Metab Pharmacokinet","first-page":"135","article-title":"Urinary excretion of phenytoin metabolites, 5-(4\u2032-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases","volume":"20","author":"Yamanaka","year":"2005"},{"key":"R22","series-title":"Bull World Health Organ","first-page":"407","article-title":"Studies on the pharmacokinetics of primaquine","volume":"59","author":"Fletcher","year":"1981"},{"key":"R23","series-title":"Eur J Clin Pharmacol","first-page":"377","article-title":"CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking","volume":"65","author":"Mahavorasirikul","year":"2009"},{"key":"R24","series-title":"Br J Clin Pharmacol","first-page":"596","article-title":"Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population","volume":"53","author":"Hamdy","year":"2002"},{"key":"R25","series-title":"Biochem Biophys Res Commun","first-page":"491","article-title":"3\u2032-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression","volume":"340","author":"Wang","year":"2006"},{"key":"R26","series-title":"Pharmacogenetics","first-page":"317","article-title":"Nicotine metabolism and CYP2A6 allele frequencies in Koreans","volume":"11","author":"Kwon","year":"2001"},{"key":"R27","series-title":"Clin Pharmacol Ther","first-page":"72","article-title":"Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans","volume":"69","author":"Nakajima","year":"2001"},{"key":"R28","series-title":"Clin Pharmacol Ther","first-page":"115","article-title":"Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism","volume":"83","author":"Mwenifumbo","year":"2008"},{"key":"R29","series-title":"Pharmacogenetics","first-page":"687","article-title":"Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C","volume":"10","author":"Ariyoshi","year":"2000"},{"key":"R30","series-title":"FEBS Lett","first-page":"105","article-title":"Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population","volume":"448","author":"Oscarson","year":"1999"},{"key":"R31","series-title":"Clin Pharmacol Ther","first-page":"457","article-title":"CYP2A6 genotype and the metabolism and disposition kinetics of nicotine","volume":"80","author":"Benowitz","year":"2006"},{"key":"R32","series-title":"Mol Pharmacol","first-page":"1954","article-title":"Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor","volume":"67","author":"Burk","year":"2005"},{"key":"R33","series-title":"Arch Toxicol","first-page":"667","article-title":"Inhibition and induction of human cytochrome P450 enzymes: current status","volume":"82","author":"Pelkonen","year":"2008"},{"key":"R34","series-title":"Clin Pharmacol Ther","first-page":"32","article-title":"Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9","volume":"74","author":"Simonsson","year":"2003"},{"key":"R35","series-title":"Eur J Clin Invest","first-page":"647","article-title":"In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin","volume":"36","author":"Simonsson","year":"2006"},{"key":"R36","series-title":"Drug Metab Dispos","first-page":"1301","article-title":"Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid alpha2\/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics","volume":"35","author":"Ma","year":"2007"},{"key":"R37","series-title":"J Pharmacol Exp Ther","first-page":"906","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003"},{"key":"R38","series-title":"Clin Infect Dis","first-page":"1358","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Rodriguez-Novoa","year":"2005"},{"key":"R39","series-title":"Antivir Ther","first-page":"315","article-title":"Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children","volume":"14","author":"Puthanakit","year":"2009"},{"key":"R40","series-title":"Nature","first-page":"50","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/91\/2\/article-p361.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/91\/2\/article-p361.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/91\/2\/article-p361.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:18:16Z","timestamp":1723065496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/91\/2\/article-p361.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":40,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.13-0531","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]}}}